Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros U.S. Tech 100 Protective Allocation Monthly Index (A100PAM)
5/31/2026, 12:00:00 AM
Johnson & Johnson announced positive results from the Phase 1b/2 OrigAMI-4 clinical trial for amivantamab in treating advanced head and neck cancer, showing a 42% overall response rate in heavily pretreated patients.
Korean Translation
존슨앤드존슨, 진행성 두경부암 치료를 위한 아미반타맙의 임상 1b/2상 OrigAMI-4 연구에서 42%의 전체 반응률을 보인 긍정적인 결과를 발표함.
Related Recent Events
Microchip Technology Inc (MCHP) · Earnings Release
Next quarterly earnings for Q1 2027 are expected to be released around August 6, 2026, expected. Low impact is estimated as this is a routine scheduling announcement.
8/6/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q2 2026 earnings release is expected around August 5, 2026, based on past reporting schedules expected. Low impact estimated as the announcement of a date typically precedes the actual market-moving results.
8/5/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
Q2 2026 earnings release and conference call scheduled.
8/4/2026, 12:00:00 AM
Cummins Inc. (CMI) · Earnings Release
Q2 2026 earnings release on 2026-08-04, for which high importance is estimated due to potential 10% price impact, is scheduled.
8/4/2026, 12:00:00 AM
KLA Corp (KLAC) · Earnings Release
Fiscal Q4 2026 earnings release on July 30, 2026, is expected to have a medium importance impact on the stock price, scheduled.
7/30/2026, 12:00:00 AM
Apple Inc (AAPL) · Earnings Release
Apple's Q3 2026 earnings release is expected on July 30, 2026; analysts forecast an EPS of approximately $1.86 forecasted. Low importance is estimated as the market impact is expected to be around 1%.
7/30/2026, 12:00:00 AM